01 11Vimpat
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 1,441
2018 Revenue in Millions : 1,197
Growth (%) : 20
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 128
2019 Revenue in Millions : 95
Growth (%) : 35
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2020 Revenue in Millions : 1,755
2019 Revenue in Millions : 1,599
Growth (%) : 10
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 146
2020 Revenue in Millions : 127
Growth (%) : 24
Main Therapeutic Indication : Neurology
Currency : USD
2021 Revenue in Millions : 1,705
2020 Revenue in Millions : 1,755
Growth (%) : 7
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 161
2021 Revenue in Millions : 146
Growth (%) : 11
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 171
2022 Revenue in Millions : 161
Growth (%) : 20
Main Therapeutic Indication : Neurology
Currency : USD
2022 Revenue in Millions : 1,198
2021 Revenue in Millions : 1,705
Growth (%) : -30
Main Therapeutic Indication : Neurology
Currency : USD
2023 Revenue in Millions : 425
2022 Revenue in Millions : 1,197
Growth (%) : 185
Main Therapeutic Indication : CNS & Anesthesia
Currency : USD
2019 Revenue in Millions : 96
2018 Revenue in Millions : 69
Growth (%) : 39
LOOKING FOR A SUPPLIER?